Legislator Giurisprudenza & Legislazione
DE FR IT EN
Analizza in Legislator
3 B 63/12, 3 B 63/12 (3 C 10/13) Generato dall'IA

Pharmaceutical authorization denial: Clarifying prerequisites for rejecting combination product justification under § 25 AMG

Numero d'incarto 3 B 63/12, 3 B 63/12 (3 C 10/13)
Autorità giudiziaria
Giurisdizione Germania (DE)
Data della decisione
Esito del giudizio Accolto (Allowed)
Apri la fonte ufficiale Versione Markdown leggibile dalle macchine (.md)

Sintesi Legislator

Generato dall'IA

The Federal Administrative Court (BVerwG) granted the plaintiff's leave to appeal, finding the complaint well-founded and ruling that the case holds fundamental significance, thereby permitting a revision proceeding to further clarify the legal standards for denying pharmaceutical approval. The dispute concerned the refusal of a drug marketing authorization due to alleged insufficient justification for a combination product, challenging the administrative agency's decision under the German Medicines Act. The decisive legal basis for the admission of the appeal was § 132 Abs. 2 Nr. 1 VwGO, citing the need for judicial clarification of the prerequisites for denying authorization under § 25 Abs. 2 Satz 1 Nr. 5a AMG, with the interim matter worth in revision calculated pursuant to §§ 47, 52, and 63 GKG.

Regesto Legislator

Generato dall'IA

§ 132 Abs. 2 Nr. 1 VwGO, § 63 Abs. 1 Satz 1 GKG, § 25 Abs. 2 Satz 1 Nr. 5a AMG, § 47 Abs. 1 i.V.m. § 52 Abs. 1 und § 63 Abs. 1 Satz 1 GKG; Pharmaceutical authorization denial: Clarifying prerequisites for rejecting combination product justification under § 25 AMG: The dispute concerned the refusal of a drug marketing authorization due to alleged insufficient justification for a combination product, challenging the administrative agency's decision under the German Medicines Act. The decisive legal basis for the admission of the appeal was § 132 Abs. 2 Nr. 1 VwGO, citing the need for judicial clarification of the prerequisites for denying authorization under § 25 Abs. 2 Satz 1 Nr. 5a AMG, with the interim matter worth in revision calculated pursuant to §§ 47, 52, and 63 GKG.

Parole chiave

Generato dall'IA
merci interessate motivi di revisione oggetto della lite reclamo amministrativo censure procedurali autorizzazione ad agire

Disposizioni normative citate

Generato dall'IA
§ 132 Abs. 2 Nr. 1 VwGO
Grounds for admitting the appeal due to fundamental significance.
§ 63 Abs. 1 Satz 1 GKG
1 und § 63 Abs. 1 Satz 1 GKG.
§ 25 Abs. 2 Satz 1 Nr. 5a AMG
Substantive legal provision for the denial of pharmaceutical authorization, identified as the key issue for clarification in the revision.
§ 47 Abs. 1 i.V.m. § 52 Abs. 1 und § 63 Abs. 1 Satz 1 GKG
Basis for the provisional determination of the amount in dispute for the revision proceedings.
Generato dall'IA
3 B 27/14, 3 B 27/14 (3 C 15/15)
Preconditions for refusing extension of pharmaceutical marketing authorization based on unfavorable benefit-risk profile
3 B 69/16, 3 B 69/16 (3 C 4/18)
Standing to challenge exemption of pharmacist-manufactured drug from marketing authorization under § 42(2) VwGO and § 21 AMG
3 B 40/13
Pharmaceutical re-marketing authorization: constitutional validity of preclusion bar on deficiency-curing documents and evidentiary standards for therapeutic efficacy
3 C 3/18
Administrative-law standing to challenge prescription status of a registered medicinal product: admissibility of declaratory action against norm-giver and limits of discretion under § 48 AMG
3 C 9/16, 3 C 9/16 (3 C 18/14)
Pharmaceutical data protection: Admissibility of objection for lack of due process against refusal to refer preliminary questions on second marketing authorization applications

Questioni giuridiche chiave estratte da Legislator

Generato dall'IA
§ 132 Abs. 2 Nr. 1 VwGO

Grounds for admitting the appeal due to fundamental significance.

§ 25 Abs. 2 Satz 1 Nr. 5a AMG

Substantive legal provision for the denial of pharmaceutical authorization, identified as the key issue for clarification in the revision.

§ 47 Abs. 1 i.V.m. § 52 Abs. 1 und § 63 Abs. 1 Satz 1 GKG

Basis for the provisional determination of the amount in dispute for the revision proceedings.

Ti chiedi come si applica questa sentenza alla tua fattispecie?

Analizza questa decisione insieme alla legislazione federale e cantonale, ai commentari e alla giurisprudenza successiva in Legislator AI.

Apri in Legislator →

Testo completo

Arzneimittelzulassung; Versagung wegen unzureichender Kombinationsbegründung; Revisionszulassung

[GRUENDE]

Die Beschwerde der Klägerin ist begründet. Die Rechtssache hat grundsätzliche Bedeutung im Sinne des § 132 Abs. 2 Nr. 1 VwGO. Das Revisionsverfahren kann Gelegenheit zur weiteren Klärung der Voraussetzungen für die Versagung einer Arzneimittelzulassung nach § 25 Abs. 2 Satz 1 Nr. 5a AMG bieten.

Die vorläufige Streitwertfestsetzung für das Revisionsverfahren beruht auf § 47 Abs. 1 i.V.m. § 52 Abs. 1 und § 63 Abs. 1 Satz 1 GKG.